What question did this study set out to answer?

To determine whether baseline levels of anti-cardiolipin antibodies independently predict myocardial infarction and cardiac death in a prospective cohort of dyslipidemic men without overt autoimmune disease.

January 1, 1995Circulation

Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men

View Full Paper

Ask AI

Bookmark

Why the study?

Does the presence of high anti-cardiolipin antibody levels increase the risk of myocardial infarction or cardiac death in middle-aged dyslipidemic men?

Population

266 middle-aged dyslipidemic men participating in the Helsinki Heart Study, consisting of 133 patients with…

Comparison

High levels of anti-cardiolipin antibodies vs Lower levels of anti-cardiolipin antibodies

Design

Case-control

Follow-up

5 years

Authors

OVOuti VaaralaOrion Corporation (United Kingdom)MMMatti MänttäriJorvi Hospital VMVesa ManninenGeneral / Preventive / Lipids

Discussion

Member takes

Implication

High aCL levels were associated with doubled MI risk in dyslipidemic men; leaves open whether screening or intervention improves outcomes.

Key Points

To determine whether baseline levels of anti-cardiolipin antibodies independently predict myocardial infarction and cardiac death in a prospective cohort of dyslipidemic men without overt autoimmune disease.
Conducted a nested case-control study of 133 men experiencing myocardial infarction or cardiac death and 133 controls matched for geographical area and treatment arm from the 5-year Helsinki Heart Study.
Measured baseline serum levels of IgG-class antibodies to cardiolipin and oxidized LDL using ELISA.
Estimated relative risk using logistic regression adjusted for traditional risk factors, including age, smoking, systolic blood pressure, and cholesterol levels.
Baseline anti-cardiolipin antibody optical density was significantly higher in cardiac cases than in controls (0.417 vs. 0.361; P < .005).
Participants with anti-cardiolipin antibody levels in the highest quartile demonstrated an increased relative risk of myocardial infarction of 2.0 (95% CI, 1.1 to 3.5), independent of standard lipid and cardiovascular risk factors.
Anti-cardiolipin antibody levels positively correlated with antibodies to oxidized LDL (r = .40, P < .001), producing an additive increase in cardiac risk.

Structured PICO

Does the presence of high anti-cardiolipin antibody levels increase the risk of myocardial infarction or cardiac death in middle-aged dyslipidemic men?

Population

266 middle-aged dyslipidemic men (non-high-density lipoprotein cholesterol ≥ 5.2 mmol/L) participating in the Helsinki Heart Study, consisting of 133 patients with myocardial infarction or cardiac death and 133 matched control subjects.

Intervention

High levels of anti-cardiolipin (aCL) antibodies (highest quartile of distribution)

Comparator

Lower levels of anti-cardiolipin (aCL) antibodies (remainder of the population)

Outcome

Myocardial infarction or cardiac deathhard clinical

High anti-cardiolipin antibody levels are an independent risk factor for myocardial infarction or cardiac death in middle-aged dyslipidemic men without overt autoimmune disease.

Cite This Study

Vaarala et al. (1995) studied this question.

synapsesocial.com/papers/6a8714e6cbc6304817befb8f https://doi.org/10.1161/01.cir.91.1.23

View Full Paper

Ask AI

Bookmark

Implication

High aCL levels were associated with doubled MI risk in dyslipidemic men; leaves open whether screening or intervention improves outcomes.

Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged Men

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider